Martin E. Gleave

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 436 publications

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Journal: Future oncology (London, England)

Published: July 06, 2026

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.

Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.

Journal: Oncogene

Published: March 30, 2026

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Journal: Urologic oncology

Published: March 06, 2026

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

Journal: Cells

Published: February 11, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Journal: The Journal of urology

Published: December 09, 2025

Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer.

Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 04, 2025

Micro-ultrasound transperineal prostate biopsy as an alternative to MRI-US fusion transrectal biopsy.

Micro-ultrasound transperineal prostate biopsy as an alternative to MRI-US fusion transrectal biopsy.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: November 05, 2025

Showing 1-12 of 436

Last Updated: 09/26/2026